Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: young a. Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350. Health Technol Assess. 2016. PMID: 27140438 Free PMC article. Review.
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A. Stevenson M, et al. Among authors: young a. Health Technol Assess. 2016 Nov;20(35):611-614. doi: 10.3310/hta20350-c201611. Health Technol Assess. 2016. PMID: 27919316 Free article. No abstract available.
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL. Stevenson MD, et al. Among authors: young a. J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15. J Rheumatol. 2017. PMID: 28202743 Free article. Review.
The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards.
Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, Everson HE, Scott D, Young A, Paisley S, Williams K. Wailoo AJ, et al. Among authors: young a. Value Health. 2014 Nov;17(7):A380. doi: 10.1016/j.jval.2014.08.2611. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200840 Free article. No abstract available.
Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.
Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A, Verstappen SM. Norton S, et al. Among authors: young a. Semin Arthritis Rheum. 2014 Oct;44(2):131-44. doi: 10.1016/j.semarthrit.2014.05.003. Epub 2014 May 9. Semin Arthritis Rheum. 2014. PMID: 24925692 Free PMC article. Review.
7,740 results